The increasing number of people with advanced Alzheimer's disease (AD) represents a
significant psychological and financial cost to the world population. Accurate detection of the …

Biomarkers that predict the clinical onset of Alzheimer's disease (AD) enable the
identification of individuals in the early, preclinical stages of the disease. Detecting AD at this …

Both plasma biomarkers and brain network topology have shown great potential in the early
diagnosis of Alzheimer's disease (AD). However, the specific associations between plasma …

Neurofilaments light chain (NfLs) are currently recognized as a marker of axonal injury and
degeneration. Their measurement in biological fluids has a promising role in the diagnosis …

White matter dementia (WMD) is a concept introduced in 1988 to highlight the importance of
white matter pathology in producing cognitive dysfunction and dementia. Whereas gray …

INTRODUCTION Long‐term blood pressure variability (BPV) and plasma neurofilament light
(pNfL) have been identified as potential biomarkers for Alzheimer's disease (AD) and …

Background: Neurofilament Light (NfL) is a biomarker for early neurodegeneration in
Alzheimer's disease (AD). This study aims to examine the association between plasma NfL …

The plasma neurofilament light chain (NfL), an axonal cytoskeleton protein, increases in
Alzheimer disease and was therefore proposed as a blood-based biomarker of the disease …

Alzheimer's Disease (AD) is characterized by cognitive impairments and memory difficulties,
which cause daily activities, and personal and behavioral problems. In recent years blood …

This article aimed to review the chemical and pharmacological aspects of berberine,
correlating them with the pathophysiological outcome of Alzheimer's disease (AD). A …